COVID-19 Science Spotlight

Here are my thoughts on how developing data may help you assess immunocompromised patients’ risk of severe COVID-19 illness.

Christopher J. Lehmann, MD Gregory Olson, MD Renslow Sherer, MD Released: June 10, 2021

Navigating what is currently known about responsiveness to COVID-19 vaccines and the potential for SARS-CoV-2 variants in immunocompromised patients.

Christopher J. Lehmann, MD Gregory Olson, MD Renslow Sherer, MD Released: June 28, 2021

Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: July 7, 2021

My take on the potential utility of casirivimab plus imdevimab for hospitalized patients with COVID-19 who have higher viral burden and delayed antibody responses.

Arthur Kim, MD Released: August 3, 2021

In 2020, New York City was an epicenter of the COVID-19 pandemic, and race-related disparities in patients with COVID-19 presenting to our hospital were evident. Here’s my take on 4 new analyses showing that increased risk of COVID-19 illness and poorer outcomes reflect the preexisting, deep socioeconomic inequities that affect health and access to healthcare.

Vikramjit Mukherjee, MD Released: August 4, 2021

In this commentary, I review recent studies assessing the potential role for TDF in limiting SARS-CoV-2 replication.

Josep M. Llibre, MD, PhD Released: August 16, 2021

What if one in 4 COVID-19 deaths during a surge could be avoided? My take on important new data showing that COVID-19 caseload surges adversely affect COVID-19 mortality rates.

Vikramjit Mukherjee, MD Released: September 3, 2021

Do we already have an FDA-approved, safe, and inexpensive drug that could benefit patients with COVID-19? Take a look at these promising studies of a repurposed drug—fluvoxamine—for COVID-19.

Paul E. Sax, MD Released: September 21, 2021